Goldman Sachs Raises Insmed PT to $225, Maintains Buy Rating

Friday, Oct 31, 2025 2:18 pm ET1min read
INSM--

Goldman Sachs Raises Insmed PT to $225, Maintains Buy Rating

Goldman Sachs Raises Insmed PT to $225, Maintains Buy Rating

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet